Vaginal atrophy: when estrogen has done its job and the pain has not listened.

The tissue is treated, the exam looks better, and intercourse still hurts. There is an explanation that does not involve giving up.

This page is about understanding the condition and the role the brain and nervous system can play in it. It is not a diagnosis. Your own clinicians know your case.

What vaginal atrophy is

Estrogen keeps the tissues of the vagina, vulva, urethra and bladder thick, elastic and well supplied with blood. When estrogen falls, most often after menopause but also with breastfeeding, some cancer treatments and certain medications, these tissues become thinner, drier and more fragile. The result is vaginal atrophy, which doctors now call genitourinary syndrome of menopause (GSM) because it affects the urinary tract too. Symptoms include dryness, burning, itching, pain and bleeding with intercourse, urinary urgency and frequency, and recurrent urinary tract infections.

It is very common and very treatable. Low-dose vaginal estrogen is the most effective treatment and restores the tissue over weeks to months. Vaginal moisturisers, lubricants, non-hormonal prescription options and pelvic floor physiotherapy also help.

The neuroplastic contribution

The ATNS Index of Neuroplastic Symptoms says vaginal atrophy is not caused by neuroplastic symptoms. It then adds that if the symptoms attributed to the condition are not typical, if the course over time is not as expected, or if the response to treatment is less than anticipated, an evaluation for neuroplastic symptoms should be done as a potential contributor.

Neuroplastic symptoms are real symptoms produced by learned pathways in the brain and nervous system, a sensitized alarm system, rather than by ongoing damage or disease in the tissue. They are not imaginary and not a sign of anything being wrong with you as a person, and because the brain can change, they are reversible. In the pelvis, the nervous system contribution is particularly common, because the area is richly supplied with nerves and closely tied to emotion, safety and memory:

• Months of painful intercourse teach the nervous system that penetration is dangerous. After the tissue is restored, the brain may still predict pain and produce it.
• The pelvic floor muscles tighten protectively in anticipation, which causes its own pain and can feel exactly like atrophy.
• Burning and rawness can persist after the tissue has healed, because the nerves have become sensitized, a pattern overlapping with vulvodynia.

The signal that this is happening is a mismatch: the examination shows healthy, estrogenised tissue, and the pain or burning continues. That mismatch is not a treatment failure; it is a different problem with its own approach. See also the vaginismus and chronic pelvic pain articles.

What the research shows

A review of the epidemiology, physiopathology, clinical features and diagnosis of genitourinary syndrome of menopause describes the hormonal mechanism and the range of symptoms, and states that vaginal estrogen therapy restores the tissue and is currently the best treatment. It is the foundation: the tissue problem has an effective tissue treatment, and that should come first.

A critical review of dyspareunia (painful intercourse) in postmenopausal women found that it is common but correlates only weakly with estrogen levels or the degree of atrophy, and that a substantial share of women with it do not have a low-estrogen cause. In other words, thin tissue does not fully explain who hurts and who does not.

A matched study of women newly diagnosed with vulvovaginal atrophy and dyspareunia found higher rates of depression (23.9% vs 18.9%) and anxiety (16.6% vs 11.3%) than in women without it, with the largest gap in younger women, and the link held after adjusting for menopause-related factors. The design cannot say which comes first, but it shows that mood and threat are part of this picture.

A clinical review of the evaluation and treatment of female sexual pain lays out a biopsychosocial approach. It identifies vaginal atrophy, vulvodynia, pelvic floor overactivity and myofascial pain as overlapping causes of dyspareunia, and reports that cognitive behavioural therapy, used alongside other treatments, reduces the anxiety and fear associated with painful intercourse.

Honest limits: there are no trials of brain-based approaches in women whose symptoms persist after estrogen, and the psychological treatment evidence in vulvodynia is still thin.

Signs the nervous system may be part of the picture

• Your clinician says the tissue looks well estrogenised, but pain, burning or rawness continue.
• Pain is present at the entrance to the vagina even with a lubricant, or before penetration begins.
• Burning is constant or comes on with sitting, tight clothing or stress, not only with intercourse.
• You tense up or feel dread in anticipation of intimacy.

A solution that addresses it

There is an approach that works on the brain's contribution to pelvic pain. Often called pain reprocessing, it combines education about neuroplastic symptoms, somatic tracking (observing pelvic sensations with curiosity rather than dread), reducing fear and threat, a graded and self-paced return to touch and intimacy, emotional awareness and expression, and acceptance and commitment skills. Trained clinicians deliver it, often alongside pelvic floor physiotherapy, and digital programs are increasingly available.

Cindra is a daily AI companion built around these approaches, with daily check-ins, short practices and plain-language lessons for people whose symptoms have a neuroplastic component. If your symptoms have outlasted a treatment that should have worked, you can join the waitlist. For the underlying science, see why chronic pain persists.

What to do next

First, make sure the tissue problem is properly treated. If you have never been offered vaginal estrogen or another prescription treatment, ask about it; many women are not. If you are using treatment, give it the two to three months it needs, and keep using it; do not stop on your own.

Second, ask for a re-examination. If the tissue now looks healthy and symptoms persist, ask your clinician the ATNS question: could a sensitized nervous system or pelvic floor be contributing? Ask about pelvic floor physiotherapy and about vulvodynia as an overlapping diagnosis.

Third, if it fits, start practising. Reduce fear around touch with graded, self-controlled steps, use somatic and mindfulness practices to settle the pelvic floor, and address the emotional weight of the experience rather than pushing through it.

Seek prompt medical attention for bleeding after menopause that has not been investigated, a vulval lump, sore or skin change that does not heal, blood in the urine, or pelvic pain with fever.

This article is for general education and is not medical advice, and it does not diagnose or treat any condition. Persistent symptoms deserve a proper medical assessment to rule out disease or injury before a neuroplastic explanation is considered. If your symptoms are new, changing, or come with red-flag signs such as fever, unexplained weight loss, numbness or weakness, chest pain, or loss of bladder or bowel control, see a clinician promptly.